Table 2

Vaccine efficacy parameters and assumptions
Gender Male Female
HPV genotype 6 11 16 18 6 11 16 18
Against transient infection†,‡
- Cervical, vaginal & vulvar diseases 41.1 62.1 76.0 96.3
- Genital warts & HPV 6, 11 49.0 57.0 76.1 76.1
Against persistent infection
- Anal disease 78.7 96.0 98.8 98.4
- Cervical, vaginal & vulvar diseases 98.8 98.4
- Penile disease 78.7 96.0
Against individual diseases
- Genital warts 84.3 90.9 98.9 100.0

Unit: percentage. Values were derived from [17].

Efficacy against genital infection in males is assumed to prevent transmission of genital infection to females, and vice versa.

Efficacy for 1 and 2 doses assumed to be 23% and 45% of efficacy of the full 3 doses, respectively.

*Efficacy against anal, head and neck, penile cancers is conferred through protection against infection only.

Marty et al.

Marty et al. BMC Cancer 2013 13:10   doi:10.1186/1471-2407-13-10

Open Data